Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HNRNPH1 regulates cell cycle-associate genes in glioblastoma

ABSTRACT: Glioblastoma (GBM) is an aggressive and deadly brain tumor with a poor prognosis despite advances in therapeutic intervention. Clinical trials of targeted therapy, anti-angiogenic agents, gene therapy, and immunotherapy have led to some extension of the length of GBM patient survival. However, a cure for GBM remains elusive, and almost all tumors recur in a more aggressive form for which there is no standard of care. One critical reason for GBM resistance to current therapies can be attributed to the tumor’s extensive heterogeneity and the presence of different mechanisms that promote GBM progression. Post-transcriptional regulation of messenger RNAs participates in many cancer processes, and it is usually controlled by several different RNA-binding proteins. Dysregulation of RNA-binding protein expression alters RNA metabolism and results in the production of abnormal proteins that promote cancer development. In this study, we performed transcriptome analysis of HNRNPH1 knockout cells and showed that silencing HNRNPH1 reduced the expression of genes involved in cell cycle regulation. Our findings suggest RNA-binding proteins as novel targets for the development of more effective therapies for GBM.

ORGANISM(S): Homo sapiens

PROVIDER: GSE294345 | GEO | 2026/04/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Effects of HNRNPH1 silencing on global transcriptomic changes in glioblastoma

Project description:Glioblastoma (GBM) is an aggressive and deadly brain tumor with a poor prognosis despite advances in therapeutic intervention. Clinical trials of targeted therapy, anti-angiogenic agents, gene therapy, and immunotherapy have led to some extension of the length of GBM patient survival. However, a cure for GBM remains elusive, and almost all tumors recur in a more aggressive form for which there is no standard of care. One critical reason for GBM resistance to current therapies can be attributed to the tumor’s extensive heterogeneity and the presence of different mechanisms that promote GBM progression. Post-transcriptional regulation of messenger RNAs participates in many cancer processes, and it is usually controlled by several different RNA-binding proteins. Dysregulation of RNA-binding protein expression alters RNA metabolism and results in the production of abnormal proteins that promote cancer development. In this study, we performed transcriptome analysis of HNRNPH1 knockout cells and showed that silencing HNRNPH1 reduced the expression of genes involved in cell cycle regulation. Our findings suggest RNA-binding proteins as novel targets for the development of more effective therapies for GBM.

2026-04-08 | GSE294242 | GEO

HNRNPH1 is required for rhabdomyosarcoma cell growth and survival

Project description:Rhabdomyosarcoma (RMS) is an aggressive and difficult to treat cancer characterized by a muscle-like phenotype. Although the average 5-year survival rate is 65% for newly diagnosed RMS, the treatment options for metastatic disease are limited in efficacy, with the 5-year survival rate plummeting to 30%. Heterogenous nuclear ribonucleoprotein H1 (HNRNPH1) is an RNA-binding protein that is highly expressed in many cancers, including RMS. To determine the role HNRNPH1 plays in RMS tumorigenesis, we investigated its expression and effect on growth in 3 cellular models of RMS: RD, RH30, and RH41 cells. Upon knockdown of HNRNPH1, growth of all cell lines was dramatically reduced, most likely through a combination of apoptosis and cell cycle arrest. We then recapitulated this finding by performing in vivo xenograft studies, in which knockdown of HNRNPH1 resulted in a striking reduction in tumor formation and growth. We used RNA sequencing to identify changes in gene expression after HNRNPH1 knockdown and found altered splicing of some oncogenes. Our data show that HNRNPH1 may be an important molecular target for the development of future RMS therapy.

2018-02-02 | GSE104559 | GEO

The E3 ligase TRIM25 impairs apoptotic cell death in colon carcinoma cells through hnRNPH1-triggered destabilization of caspase-7 mRNA

Project description:Therapy resistance is still a major reason for treatment failure in colorectal cancer (CRC). Previously, we identified the E3 ubiquitin ligase TRIM25 as a novel suppressor of caspase-2 translation, thereby contributing to apoptosis resistance of CRC cells towards chemotherapeutic drugs. We herein report the executioner caspase-7 being a further target of TRIM25. Results from gain and loss-of-function approaches and actinomycin D experiments indicate that TRIM25 attenuates caspase-7 expression mainly through a decrease in mRNA stability. Data from RNA pull-down assays with immunoprecipitated TRIM25 truncations indicate a direct TRIM25 binding to caspase-7 mRNA which is mediated by the PRY/SPRY domain which is also known to be highly relevant for protein-protein interactions. By employing TRIM25 immunoprecipitation, we identified the heterogeneous nuclear ribonucleoprotein H1 (hnRNPH1) as a novel TRIM25 binding protein involved in the control of caspase-7 mRNA stability. Notably, the interaction of both proteins was highly sensitive to RNase A treatment and again depended on the PRY/SPRY domain, thus indicating an indirect interaction of both proteins which is achieved through a common RNA binding. Ubiquitin affinity chromatography showed that hnRNPH1 and TRIM25 are targets of ubiquitin modification. Functionally, the ectopic expression of caspase-7 in CRC cells caused an increase in poly ADP-ribose polymerase (PARP) cleavage concomitant with a significant increase in apoptosis. Collectively, the negative regulation of caspase-7 by TRIM25 via hnRNPH1 implies a novel survival mechanism underlying chemotherapeutic drug resistance of CRC cells. Targeting of TRIM25 could therefore offer a promising strategy for reducing therapy resistance in CRC patients.

2023-01-05 | PXD037182 | Pride

Expression profiling of the TC32 Ewing sarcoma cell line following silencing of SUPT6H, SF3B1 or HNRNPH1

Project description:The investigation of the function of SUPT6H, SF3B1 and HNRNPH1 in Ewing sarcoma The expression profiles of TC32 Ewing sarcoma cells were determine 48 hours post siRNA-transfected. Groups consisted of untreated cells (three samples), and negative control (siNeg) transfected-TC32 cells (six samples), and TC32 cells in which either SUPT6H, SF3B1 or HNRNPH1 were silenced; three different siRNAs corresponding to each gene were assessed separately.

2016-01-15 | E-GEOD-67736 | biostudies-arrayexpress

HNRNPH controls alternative splicing cooperatively on a transcriptome-wide scale [in vitro iCLIP]

Project description:The in vitro binding potential of HNRNPH1 to RNA is not available. Hence, we performed an high-throughput in vitro binding assay for recombinant MBP-HNRNPH1 using an RNA oligo library consisting of 2000 individual sequences. We used this in vitro binding assay to map binding of recombinant HNRNPH1 protein to RNA in individual nucleotide resolution. To understand the impact of RNA G-quadruplex structures for HNRNPH1 binding, we compared the binding of HNRNPH1 to GTP RNA and 7-deaza-GTP RNA.

2026-04-14 | GSE304723 | GEO

Expression profiling of the TC32 Ewing sarcoma cell line following silencing of SUPT6H, SF3B1 or HNRNPH1

Project description:The investigation of the function of SUPT6H, SF3B1 and HNRNPH1 in Ewing sarcoma

2016-01-15 | GSE67736 | GEO

RNA sequencing of C57BL/6J mice, heterozygous for knockout of Hnrnph1 gene, as well as C57BL/6J mice controls

Project description:Previous studies of congenic lines of C57BL/6J-DBA/2J mice compared to C57BL/6 mice revealed a 0.23 QTL for sensitivity to methamphetamine on chromosome 11, which contains two protein coding genes, Rufy1 and Hnrnph1. Subsequent transcription activator-like effector nucleases (TALENs)-mediated introduction of frameshift deletions in the first coding exon of one copy of Hnrnph1 of C57BL/6J mice, revealed comparable association to phenotype. Analysis of the transcriptome and splicesome between these Hnrnph1 heterozygous knockouts and C57BL/6J mice revealed genome-wide differentially expression and exon usage of more than 1000 genes in either.

2017-02-01 | GSE76929 | GEO

Enriched EWSR1 and EWS-FLI1 RNA-seq of HNRNPH1-silenced TC32 Ewing sarcoma and 293T human embryonic kidney cells.

Project description:Identification of EWSR1 and EWS-FLI1 transcript variants associated with the silencing of HNRNPH1 in TC32 Ewing sarcoma and 293T human embryonic kidney (HEK-293T) cells.

2019-09-20 | GSE119974 | GEO

HNRNPH1 regulates cell cycle-associate genes in glioblastoma

Project description:HNRNPH1 regulates cell cycle-associate genes in glioblastoma

| PRJNA1249067 | ENA

Density Gradients Separate Dormant and Treatment-Resistant Human Glioblastoma Cells

Project description:Glioblastoma (GBM) is among the most aggressive cancers. Despite aggressive radiotherapy and treatment with the alkylating agent temozolomide (TMZ), patients ultimately succumb to the disease. Although much interest has focused on highly tumorigenic GBM stem cells (GSCs), adaption of a concept from microbial research proposes that a minor population of dormant âpersisterâ cells in cancer evade current therapies. To separate dormant and treatment-resistant tumor cells in human GBM tumorspheres, we have refined density gradient protocols previously used for separation of neurosphere-forming neural stem cells (NSCs). We find that a minor cell population in human GBM tumorsphere cultures and patient-derived tumor biopsies display increased cell density. These high-density GBM cells (HDGCs) display dormancy, variable expression of proposed GSC markers, and 10-100 fold higher levels of reprogramming gene expression compared to low-density GBM cells (LDGCs). Transcriptional profiling data confirmed the slow-cycling state of HDGCs. As a result, HDGCs show decreased tumorsphere formation capacity in vitro and reduced tumorigenicity in vivo. Using tumorspheres and xenografts, we demonstrated that HDGCs show increased treatment-resistance to ionizing radiation (IR) and temozolomide treatment compared to LDGCs. Similar to the NSC lineage, our data suggest that dormant HDGCs become increasingly sensitive to anti-proliferative therapies as they become activated and further differentiate. In conclusion, density gradients represents a marker-independent approach to separate dormant and treatment-resistant tumor cells in human GBMs and other solid cancers. 12 samples, no replicates, derived from 5 individual patients

2016-07-01 | E-GEOD-71116 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data